⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819605 | 1.00 | — | — | |
| SCHEMBL863207 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL317547 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL76364 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL863289 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL863208 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL987158 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL985625 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL987686 | 0.86 | EPHX2 (0.33) | — | |
| SCHEMBL20357691 | 0.84 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3040329-B1 | AROMATIC COMPOUND AND USE THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH BONE METABOLISM | KYOTO PHARMA IND (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-10059663-B2 | Aromatic compound and use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-8222381-B2 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2012-07-17 | — | — | US | disclosed |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| EP-2035407-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142584-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142584-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-5106860-A | Treating inflammation, circulatory disease, gastrointestinal ulceration, allergies | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-04-21 | — | — | US | disclosed |
| US-4992455-A | Cardiovascular disorders | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0292305-A1 | Novel thiazolidin-4-one derivatives and acid addition salts thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-11-23 | — | — | EP | disclosed |